
Anthony L. Bacon
Examiner (ID: 18948, Phone: (571)270-5623 , Office: P/3747 )
| Most Active Art Unit | 3747 |
| Art Unit(s) | 4159, 3747 |
| Total Applications | 545 |
| Issued Applications | 419 |
| Pending Applications | 0 |
| Abandoned Applications | 131 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18497291
[patent_doc_number] => 20230219905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/075646
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12992
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075646
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/075646 | Aldoketo reductase inhibitors and uses thereof | Dec 5, 2022 | Issued |
Array
(
[id] => 20645765
[patent_doc_number] => 12600699
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-14
[patent_title] => Thiosemicarbazates and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/073689
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 21647
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18073689
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/073689 | THIOSEMICARBAZATES AND USES THEREOF | Dec 1, 2022 | Issued |
Array
(
[id] => 18284331
[patent_doc_number] => 20230099803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => OXAZOLIDINONE FOR TREATMENT OF INFECTIONS WITH MYCOBACTERIUM TUBERCULOSIS
[patent_app_type] => utility
[patent_app_number] => 18/060823
[patent_app_country] => US
[patent_app_date] => 2022-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060823
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060823 | Oxazolidinone for treatment of infections with | Nov 30, 2022 | Issued |
Array
(
[id] => 18420045
[patent_doc_number] => 20230174506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/060922
[patent_app_country] => US
[patent_app_date] => 2022-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060922
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060922 | (Di)amination of activated allene compounds, derivatives thereof, and methods for synthesis of the same | Nov 30, 2022 | Issued |
Array
(
[id] => 18709112
[patent_doc_number] => 20230331712
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE
[patent_app_type] => utility
[patent_app_number] => 17/992294
[patent_app_country] => US
[patent_app_date] => 2022-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17992294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/992294 | SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | Nov 21, 2022 | Abandoned |
Array
(
[id] => 19060116
[patent_doc_number] => 11939324
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
[patent_app_type] => utility
[patent_app_number] => 18/058109
[patent_app_country] => US
[patent_app_date] => 2022-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 9
[patent_no_of_words] => 13462
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058109
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/058109 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | Nov 21, 2022 | Issued |
Array
(
[id] => 18326184
[patent_doc_number] => 20230124312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR REDUCING SIGNS OR SYMPTOMS OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM
[patent_app_type] => utility
[patent_app_number] => 17/988909
[patent_app_country] => US
[patent_app_date] => 2022-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17988909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/988909 | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium | Nov 16, 2022 | Issued |
Array
(
[id] => 19209498
[patent_doc_number] => 11998533
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Pharmaceutical compositions comprising LTV-17 and beta-lactamase inhibitors and their use as antibacterial agents
[patent_app_type] => utility
[patent_app_number] => 17/984553
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3333
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17984553
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/984553 | Pharmaceutical compositions comprising LTV-17 and beta-lactamase inhibitors and their use as antibacterial agents | Nov 9, 2022 | Issued |
Array
(
[id] => 18311375
[patent_doc_number] => 20230115275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING
[patent_app_type] => utility
[patent_app_number] => 17/983645
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34679
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983645
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983645 | Amide compounds and method for making and using | Nov 8, 2022 | Issued |
Array
(
[id] => 18359443
[patent_doc_number] => 20230141034
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => ADAMANTANE-1-CARBONYL THIOUREA, AS P2X RECEPTOR ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 17/976139
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17976139
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/976139 | ADAMANTANE-1-CARBONYL THIOUREA, AS P2X RECEPTOR ANTAGONIST | Oct 27, 2022 | Abandoned |
Array
(
[id] => 18980083
[patent_doc_number] => 11905243
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Alkylaminoproline derivatives as alpha-2-delta-1 blockers
[patent_app_type] => utility
[patent_app_number] => 17/975652
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14332
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975652
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975652 | Alkylaminoproline derivatives as alpha-2-delta-1 blockers | Oct 27, 2022 | Issued |
Array
(
[id] => 18604639
[patent_doc_number] => 11746088
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Deuterated tryptamine derivatives and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/974007
[patent_app_country] => US
[patent_app_date] => 2022-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34889
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17974007
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/974007 | Deuterated tryptamine derivatives and methods of use | Oct 25, 2022 | Issued |
Array
(
[id] => 18305933
[patent_doc_number] => 20230109833
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/964994
[patent_app_country] => US
[patent_app_date] => 2022-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 679
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964994
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/964994 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | Oct 12, 2022 | Abandoned |
Array
(
[id] => 18223576
[patent_doc_number] => 20230062570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
[patent_app_type] => utility
[patent_app_number] => 17/962096
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/962096 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | Oct 6, 2022 | Abandoned |
Array
(
[id] => 18223824
[patent_doc_number] => 20230062818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => IRAK INHIBITORS AND METHOD FOR MAKING AND USING
[patent_app_type] => utility
[patent_app_number] => 17/953570
[patent_app_country] => US
[patent_app_date] => 2022-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17953570
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/953570 | IRAK inhibitors and method for making and using | Sep 26, 2022 | Issued |
Array
(
[id] => 18269336
[patent_doc_number] => 20230090578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => METHODS OF INHIBITING TUMOR METASTASIS
[patent_app_type] => utility
[patent_app_number] => 17/941371
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941371
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/941371 | METHODS OF INHIBITING TUMOR METASTASIS | Sep 8, 2022 | Abandoned |
Array
(
[id] => 19511980
[patent_doc_number] => 20240343666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => PERINAPHTHENONE COMPOUND AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/294886
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18294886
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/294886 | PERINAPHTHENONE COMPOUND AND USE THEREOF | Sep 5, 2022 | Pending |
Array
(
[id] => 18980098
[patent_doc_number] => 11905258
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
[patent_app_type] => utility
[patent_app_number] => 17/893091
[patent_app_country] => US
[patent_app_date] => 2022-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 26
[patent_no_of_words] => 40525
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893091
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893091 | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases | Aug 21, 2022 | Issued |
Array
(
[id] => 18837665
[patent_doc_number] => 11845726
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-19
[patent_title] => C
[patent_app_type] => utility
[patent_app_number] => 17/893113
[patent_app_country] => US
[patent_app_date] => 2022-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 35
[patent_no_of_words] => 26631
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893113 | C | Aug 21, 2022 | Issued |
Array
(
[id] => 19600996
[patent_doc_number] => 20240391876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/684808
[patent_app_country] => US
[patent_app_date] => 2022-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7927
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18684808
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/684808 | QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS | Aug 18, 2022 | Pending |